desipramine has been researched along with Parkinson Disease in 30 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 6.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| " In a 14-week randomized trial comparing pramipexole with sertraline in depressed patients without motor complications, the Hamilton Depression Rating Scale score decreased in both groups; however, in the pramipexole group, the proportion of patients who recovered was significantly higher." | 4.87 | Treatment of depressive symptoms in Parkinson's disease. ( Barone, P, 2011) |
| "We have investigated the effect of istradefylline on depression-like behaviors using the rat learned helplessness (LH) model." | 3.80 | Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. ( Jenner, P; Kanda, T; Kobayashi, M; Mori, A; Ohta, T; Shiozaki, S; Yamada, K, 2014) |
| "Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD)." | 2.73 | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. ( Bordet, R; Cottencin, O; Defebvre, L; Destée, A; Devos, D; Dujardin, K; Moreau, C; Poirot, I; Thomas, P, 2008) |
| "All patients with PD and orthostatic hypotension had abnormal blood pressure responses to the Valsalva maneuver and septal and lateral ventricular myocardial concentrations of 6-[(18)F]fluorodopamine-derived radioactivity >2 SD below the normal mean." | 2.70 | Orthostatic hypotension from sympathetic denervation in Parkinson's disease. ( Bruce, SR; Dendi, R; Goldstein, DS; Holmes, CS; Li, ST, 2002) |
| "In a 39-year-old man with Parkinson's disease and a history of anxiety disorders, anxiety-provoking situations such as group psychotherapy precipitated panic attacks and caused pronounced worsening of the parkinsonian symptoms." | 1.27 | Parkinson's disease complicated by anxiety. ( Ahlskog, JE; Black, JL; Routh, LC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Konieczny, J | 1 |
| Lorenc-Koci, E | 1 |
| Luo, Y | 1 |
| Li, Z | 1 |
| Peng, X | 1 |
| Xia, L | 1 |
| Ma, L | 1 |
| Szkilnik, R | 1 |
| Brus, R | 1 |
| Malinowska-Borowska, J | 1 |
| Nowak, D | 1 |
| Waliczek, M | 1 |
| Kostrzewa, RM | 1 |
| Nowak, P | 1 |
| Yamada, K | 1 |
| Kobayashi, M | 1 |
| Shiozaki, S | 1 |
| Ohta, T | 1 |
| Mori, A | 1 |
| Jenner, P | 1 |
| Kanda, T | 1 |
| Lee, MY | 1 |
| Hong, S | 1 |
| Kim, N | 1 |
| Shin, KS | 1 |
| Kang, SJ | 1 |
| Dupre, KB | 1 |
| Eskow, KL | 1 |
| Barnum, CJ | 2 |
| Bishop, C | 2 |
| Okun, MS | 1 |
| Fernandez, HH | 1 |
| Engler, H | 1 |
| Doenlen, R | 1 |
| Riether, C | 1 |
| Engler, A | 1 |
| Niemi, MB | 1 |
| Besedovsky, HO | 1 |
| del Rey, A | 1 |
| Pacheco-López, G | 1 |
| Feldon, J | 1 |
| Schedlowski, M | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Barone, P | 1 |
| Bhide, N | 1 |
| Lindenbach, D | 1 |
| Surrena, MA | 1 |
| Goldenberg, AA | 1 |
| Tignor, S | 1 |
| Klioueva, A | 1 |
| Walters, H | 1 |
| Lee, KH | 1 |
| Blaha, CD | 1 |
| Harris, BT | 1 |
| Cooper, S | 1 |
| Hitti, FL | 1 |
| Leiter, JC | 1 |
| Roberts, DW | 1 |
| Kim, U | 1 |
| Devos, D | 1 |
| Dujardin, K | 1 |
| Poirot, I | 1 |
| Moreau, C | 1 |
| Cottencin, O | 1 |
| Thomas, P | 1 |
| Destée, A | 1 |
| Bordet, R | 1 |
| Defebvre, L | 1 |
| Aebert, K | 1 |
| Jorga, KM | 1 |
| Fotteler, B | 1 |
| Modi, M | 1 |
| Rabbia, M | 1 |
| Goldstein, DS | 1 |
| Holmes, CS | 1 |
| Dendi, R | 1 |
| Bruce, SR | 1 |
| Li, ST | 1 |
| Routh, LC | 1 |
| Black, JL | 1 |
| Ahlskog, JE | 1 |
| Cash, R | 1 |
| Dennis, T | 1 |
| L'Heureux, R | 1 |
| Raisman, R | 1 |
| Javoy-Agid, F | 1 |
| Scatton, B | 1 |
| Nelson, SR | 1 |
| Walaszek, EJ | 1 |
| Markham, CH | 1 |
| Tolosa, E | 1 |
| Laitinen, L | 1 |
| Muscettola, GB | 1 |
| Giovannucci, M | 1 |
| Montanini, R | 1 |
| Morselli, PL | 1 |
| Garattini, S | 1 |
| Kaufmann, W | 1 |
| Butz, P | 1 |
| Wiesendanger, M | 1 |
| Boullin, DJ | 1 |
| O'Brien, RA | 1 |
| De Divitiis, E | 1 |
| Signorelli, CD | 1 |
| Cerillo, A | 1 |
| Tissot, R | 1 |
| Gaillard, JM | 1 |
| Guggisberg, M | 1 |
| Gauthier, G | 1 |
| de Ajuriaguerra, J | 1 |
| Matussek, N | 2 |
| Pohlmeier, H | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
4 reviews available for desipramine and Parkinson Disease
| Article | Year |
|---|---|
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dop | 2011 |
Pharmacology of the central nervous system.
Topics: Abnormalities, Drug-Induced; Acetylcholine; Adrenocorticotropic Hormone; Amphetamine; Anger; Angiote | 1968 |
Parkinson's disease; modern treatment.
Topics: Amantadine; Amphetamine; Antidepressive Agents; Antiparkinson Agents; Aromatic Amino Acid Decarboxyl | 1973 |
4 trials available for desipramine and Parkinson Disease
| Article | Year |
|---|---|
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Antidepressive Agents; Citalopram; Depression; Desipramine; Double-Blind Method; Female; Human | 2008 |
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine.
Topics: Adult; Antiparkinson Agents; Benzophenones; Cross-Over Studies; Desipramine; Double-Blind Method; Dr | 2000 |
Orthostatic hypotension from sympathetic denervation in Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Autonomic Nervous System Diseases; Brain; Catecholamines; Desipr | 2002 |
Desipramine in treatment of Parkinson's disease. A placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Desipramine; Drug Synergism; Fatigue; Gait; Human | 1969 |
22 other studies available for desipramine and Parkinson Disease
| Article | Year |
|---|---|
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipruritics; Corpus Striatum; Des | 2022 |
Desipramine rescues emotional memory deficit induced by low doses of reserpine.
Topics: Amygdala; Animals; Cues; Desipramine; Emotions; Fear; Long-Term Potentiation; Male; Memory; Memory D | 2017 |
Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
Topics: Animals; Behavior, Animal; Desipramine; Dopamine; Dopamine Agonists; Exploratory Behavior; Female; H | 2014 |
Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Brain; Depressi | 2014 |
Tricyclic Antidepressants Amitriptyline and Desipramine Induced Neurotoxicity Associated with Parkinson's Disease.
Topics: Adenosine Triphosphate; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antioxidants; Apop | 2015 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Desipramine; Female; Humans; Male | 2009 |
Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Cell Count; Corpus Striatum; Corticoste | 2009 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, An | 2012 |
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease.
Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; | 2006 |
[What success does L-Dopa have in the treatment of parkinsonian akinesia?].
Topics: Aged; Biperiden; Blood-Brain Barrier; Desipramine; Dihydroxyphenylalanine; Dopa Decarboxylase; Femal | 1967 |
Parkinson's disease complicated by anxiety.
Topics: Adult; Anxiety Disorders; Behavior Therapy; Combined Modality Therapy; Desipramine; Humans; Male; Pa | 1987 |
Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.
Topics: Aged; Aged, 80 and over; Brain; Dementia; Desipramine; Dopamine; Homovanillic Acid; Humans; Locus Co | 1987 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Cate | 1974 |
Relationship between desipramine plasma levels and the effect in Parkinson's syndrome.
Topics: Adult; Aged; Contracture; Desipramine; Drug Synergism; Female; Humans; Male; Middle Aged; Paralysis; | 1972 |
[Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
Topics: Aged; Carboxy-Lyases; Desipramine; Dihydroxyphenylalanine; Discrimination, Psychological; Drug Syner | 1969 |
Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Biological Transport; Blood Platelets; Carbon Isoto | 1970 |
[Desipramine in the therapy of Parkinson's disease].
Topics: Adult; Aged; Desipramine; Female; Humans; Male; Middle Aged; Parkinson Disease | 1971 |
[Treatment of Parkinsonian syndromes with two derivates of iminodibenzil: imipramine (tofranil) and desipramine (pertrofana)].
Topics: Aged; Desipramine; Female; Humans; Imipramine; Male; Middle Aged; Parkinson Disease | 1967 |
[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Topics: Adult; Aged; Anemia, Hemolytic; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Cell Count; Carb | 1969 |
[The effects of desmethylimipramine (Pertofran) on catecholamine metabolism in the central nervous system and the Parkinson syndrome].
Topics: Catecholamines; Central Nervous System; Desipramine; Humans; Parkinson Disease | 1965 |
[Investigations on the effect of desmethylimipramine-Pertofran on parkinsonism in man].
Topics: Aged; Arteriosclerosis; Desipramine; Encephalitis; Female; Humans; Male; Middle Aged; Parkinson Dise | 1965 |